Ntandja Wandji Line Carolle, Ningarhari Massih, Lassailly Guillaume, Dharancy Sébastien, Boleslawski Emmanuel, Mathurin Philippe, Louvet Alexandre
University of Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, F-59000 France.
University of Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, Lille, F-59000 France.
J Clin Exp Hepatol. 2023 Jan-Feb;13(1):127-138. doi: 10.1016/j.jceh.2022.06.013. Epub 2022 Jul 5.
Alcohol-related liver disease (ARLD) remains one of the leading causes of chronic liver disease and the prevalence of alcohol-related cirrhosis is still increasing worldwide. Thus, ARLD is one of the leading indications for liver transplantation (LT) worldwide especially after the arrival of direct-acting antivirals for chronic hepatitis C infection. Despite the risk of alcohol relapse, the outcomes of LT for ARLD are as good as for other indications such as hepatocellular carcinoma (HCC), with 1-, 5-, and 10- year survival rates of 85%, 74%, and 59%, respectively. Despite these good results, certain questions concerning LT for ARLD remain unanswered, in particular because of persistent organ shortages. As a result, too many transplantation centers continue to require 6 months of abstinence from alcohol for patients with ARLD before LT to reduce the risk of alcohol relapse even though compelling data show the poor prognostic value of this criterion. A recent pilot study even observed a lower alcohol relapse rate in patients receiving LT after less than 6 months of abstinence as long as addictological follow-up is reinforced. Thus, the question should not be whether LT should be offered to patients with ARLD but how to select patients who will benefit from this treatment.
酒精性肝病(ARLD)仍然是慢性肝病的主要病因之一,并且酒精性肝硬化的患病率在全球范围内仍在上升。因此,ARLD是全球肝移植(LT)的主要适应证之一,尤其是在用于慢性丙型肝炎感染的直接作用抗病毒药物问世之后。尽管存在酒精复饮的风险,但ARLD肝移植的结果与肝细胞癌(HCC)等其他适应证一样好,1年、5年和10年生存率分别为85%、74%和59%。尽管有这些良好的结果,但关于ARLD肝移植的某些问题仍未得到解答,特别是由于器官持续短缺。因此,太多的移植中心仍然要求ARLD患者在肝移植前戒酒6个月,以降低酒精复饮的风险,尽管有力的数据表明该标准的预后价值不佳。最近的一项试点研究甚至观察到,只要加强成瘾学随访,戒酒少于6个月的患者接受肝移植后酒精复饮率更低。因此,问题不应该是是否应该为ARLD患者提供肝移植,而是如何选择将从这种治疗中受益的患者。